anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed herein is a device for capturing data relating to a person. The device includes a memory for storing instructions for executing a program and a processing system configured to execute the instructions. When the processing system executes the instructions the processing system is configured to record consent from a person to capture and/or transmit the data. In the event that consent has been recorded, the processor enables the data to be captured and/or transmitted. Also disclosed in a device that receives a first indication that the person has given their consent, the first indication being received in the form of biometric data; and receives a second indication that the person has given their consent. The device records both the first indication and the second indication of the consent. Also disclosed is a method controlling access to a digital image of a subject, a servicing system for handling data, and processor-executable instructions for configuring a device in accordance with the disclosure.
The percentage water solubility of phenyl-b  : g -dihydroxypropyl ether or nuclear substituted derivatives thereof is increased to about ten per cent by treatment with ethyl urea or propylene glycol. The ether may be mixed with the urea or glycol and then dissolved in water or dissolved straightway in an aqueous solution of either the urea or glycol.  Ethers instanced are:-phenyl-, p-chlorophenyl-, o-tolyl-b  g -dihydroxypropyl ethers and the propylene glycol is substantially 1 : 2-dihydroxypropane.  Other methods employed are (a) preparing a solution of the ether in warm aqueous propylene glycol and then allowing to cool; (b) heating the ether mixed with propylene glycol and then adding water; (c) heating the ether with a portion of the propylene glycol and subsequently adding the remainder of the glycol and water either together or first the glycol then the water; (d) heating the ether slightly above its melting point and then adding to the propylene glycol and subsequently adding water. The last two methods are preferred for large scale practice.  In Examples (1) and (2) o-tolyl- and p - chlorophenyl - b  : g  - dihydroxypropyl ethers are dissolved in aqueous solutions of varying strengths of ethyl urea and Examples (3), (4) and (5) illustrate the use of o-tolyl-b  : g -dihydroxypropyl ether in the above methods (a), (c) and (d).ALSO:The percentage water solubility of phenyl-b : #U-dihydroxypropyl ethers and nuclear substituted derivatives thereof such as p-chlorophenyl and o -tolyl-b : #U-dihydroxypropyl ethers is increased to about 10 per cent by treatment with ethyl urea or propylene glycol (essentially 1.2 dihydroxypropane [see Group IV (b)].  Solutions obtained show anti-bacterial properties exceeding those expected by a mere increase of solubility.
Apparatus and associated methods relate to provide transient access rights to entities for creating, accessing, and/or sharing digital health content (DHC). In an illustrative example, a health content distribution system (HCDS) may generate a time-limited access token (TLAT) for authenticated users to access DHC. The TLAT, for example, may be generated based on a predetermined association of a corresponding DHC with a patient, a predetermined association of a requestor with the patient, a predetermined role of the requestor with relation to the patient, and a predetermined association between the requestor and a creator of the content. The TLAT may be further generated based on a predetermined association between the requestor and an organization associated with the patient. The HCDS may, for example, upon receiving the TLAT, transmit the corresponding DHC to be displayed at the requestor's device. Various embodiments may advantageously provide a secure on-demand health content access system.
Golden Syrian hamsters (Mesocricetus auratus) are a well-established animal model for human infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) due to their susceptibility to SARS-CoV-2 infection, robust virus replication and pathological manifestations similar to human COVID-19 pneumonia. To investigate the physiological changes upon infection in this animal model, we explored the alterations in daily energy expenditure (DEE), water turnover, body mass, body temperature, and locomotor activity in non-infected and SARS-CoV-2 infected Golden Syrian hamsters for four days post SARS-CoV-2. DEE was measured using the doubly labelled water method, which allows for the accurate estimation of carbon dioxide production and, consequently, energy expenditure in animals. Additionally, we investigated total water intake (TWI), which comprises drinking water, preformed water in food, and metabolic water. Using intraperitoneally implanted data loggers, we also monitored body core temperature and locomotor activity in some of the animals. Here we provide evidence for infected hamsters exhibiting significantly lower DEE and TWI compared to non-infected animals. We also observed an increase in body weight in the non-infected animals, while infected animals experienced weight loss. Further, infected animals showed a significantly decreased body temperature, indicating a generally lowered metabolic rate.
After operative treatment non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
Peptide having the structure comprising: N-terminal e.g. sequence penetration, S and docking domain, and S and addressing nuclear localizing signal (NLS); and C-terminal e.g. S and docking domain, is new. Peptide having the structure comprising: N-terminal e.g. sequence penetration, S and docking domain, and S and addressing NLS; and C-terminal e.g. S and docking domain, where the sequence penetration comprises at least one amino acid sequence allowing the penetration of the peptide in the cell, S corresponds to a sequence optionally spacer type and C terminal place, N terminal place or part and other cleavage site, C corresponds to a enzymatic cleavage site allowing the liberation of the inner cellular of the anchorage peptide and sequence of localization of the penetration sequence and optionally spacer, and docking domain comprises amino acid sequence of anchor of Phe-X-Phe-Pro (FXFP) or substrate of extracellular signal-regulated kinase (ERK), is new. Independent claims are included for: (1) a nucleic acid coding the peptide; (2) an expression vector comprising the nucleic acid; and (3) a kit comprising the peptide and/or the expression vector.
Liquid biopsy is a very topical issue in clinical diagnostics research nowadays. In this study, we explored and compared various analytical approaches to blood plasma analysis. Finally, we proposed a comprehensive procedure, which, thanks to the utilization of multiple analytical techniques, allowed the targeting of various biomolecules in blood plasma reflecting diverse biological processes underlying disease development. The potential of such an approach, combining proteomics, metabolomics, and vibrational spectroscopy along with preceding blood plasma fractionation, was demonstrated on blood plasma samples of patients suffering from hepatocellular carcinoma in cirrhotic terrain (n = 20) and control subjects with liver cirrhosis (n = 20) as well as healthy subjects (n = 20). Most of the applied methods allowed the classification of the samples with an accuracy exceeding 80.0 % and therefore have the potential to be used as a stand-alone method in clinical diagnostics. Moreover, a final panel of 48 variables obtained by a combination of the utilized analytical methods enabled the discrimination of the hepatocellular carcinoma samples from cirrhosis with 94.3 % cross-validated accuracy. Thus, this study, although limited by the cohort size, clearly demonstrated the benefit of the multimethod approach in clinical diagnosis.
Participants 6 to less than \<12 year of age and weighing \<30 kilogram (kg) at Day 1 received ELX 100 milligram (mg)/TEZ 50 mg /IVA 75 mg as fixed dose combination (FDC) tablets in the morning and IVA as mono tablet in the evening and those weighing more than or equal to (≥) 30 kg at Day 1 received ELX 200 mg/TEZ 100 mg /IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 96 weeks. Doses were adjusted upward with subsequent changes in weight. Participants ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 96 weeks.
The control group will receive interactive training and an educational booklet covering the definition, causes, development, and effective coping strategies for chemotherapy-related fatigue. Patients in this group will be assessed between 21:00-22:00 in the evening, without the warm water foot bath intervention. The evaluations will focus on fatigue levels and other related outcomes over the 7-day period. On the 7th day, the final interview will use the 12-Item Pediatric Oncology Fatigue Scale and the Parental Fatigue Scale for 7-12 Year Old Pediatric Oncology Patients, concluding the study.
Subjects will be testing their INR at home using an FDA approved device (INRatio monitor by Hemosense) reporting their results to Quality Assured Services (QAS) via an 800 phone number; their Primary Care Provider will receive a fax with the INR result. We ask this group of patients to test at minimum one time a week, additional testing as requested by their Primary Care Provider. This phase lasts twelve weeks, beginning on the day of discharge from our hospital.
The dose of ursodeoxycholic acid will be given at 10 mg/kg twice per day just prior to or during a feed, using a suspension of 50 mg/ml = 0.2 ml/kg. For oedematous malnutrition participants, weight is pragmatically reduced by 10%. To be prescribed and given following enrolment.
Cortical malformations such as focal cortical dysplasia type II (FCDII) are associated with pediatric drug-resistant epilepsy that necessitates neurosurgery. FCDII results from somatic mosaicism due to post-zygotic mutations in genes of the PI3K-AKT-mTOR pathway, which produce a subset of dysmorphic cells clustered within healthy brain tissue. Here we show a correlation between epileptiform activity in acute cortical slices obtained from human surgical FCDII brain tissues and the density of dysmorphic neurons. We uncovered multiple signatures of cellular senescence in these pathological cells, including p53/p16 expression, SASP expression and senescence-associated β-galactosidase activity. We also show that administration of senolytic drugs (dasatinib/quercetin) decreases the load of senescent cells and reduces seizure frequency in an MtorS2215F FCDII preclinical mouse model, providing proof of concept that senotherapy may be a useful approach to control seizures. These findings pave the way for therapeutic strategies selectively targeting mutated senescent cells in FCDII brain tissue.
The safety and efficacy of OMNISCAN at a single dose of 0.05 to 0.1 mmol/kg have been established in pediatric patients over 2 years of age based on adequate and well controlled studies of OMNISCAN in adults, a pediatric CNS imaging study, and safety data in the scientific literature. However, the safety and efficacy of doses greater than 0.1 mmol/kg and of repeated doses have not been studied in pediatric patients.

Pharmacokinetics of OMNISCAN have not been studied in pediatrics. The glomerular filtration rate of neonates and infants is much lower than that of adults. The pharmacokinetics volume of distribution is also different. Therefore, the optimal dosing regimen and imaging times in patients under 2 years of age have not been established.
INTRODUCTION: Postoperative pancreatic fistula (POPF) remains one of the most severe complications of laparoscopic pancreaticoduodenectomy (LPD). Theoretically, transecting the pancreatic neck more distally has both advantages (more blood supply, and more central pancreatic duct) and disadvantages (maybe smaller the pancreatic duct) in preventing POPF. This theoretical contradiction pushed us to organise this trial to explore the impact of the level of pancreatic transection in clinical practice. We conduct this randomised trial with the hypothesis that extended pancreatic neck transection has superiority to conventional pancreatic neck transection.
METHODS AND ANALYSIS: The LPDEXCEPT (Extended pancreatic neck transection versus conventional pancreatic neck transection during laparoscopic pancreaticoduodenectomy) trial is a multicentre, randomised-controlled, open-label, superiority trial in 4 centres whose annual surgical volume for LPD is more than 25 cases with pancreatic surgeons who had completed their learning curve. A total of 154 patients who meet the inclusive and exclusive criteria are randomly allocated to the extended pancreatic neck transection group or conventional pancreatic neck transection group in a 1:1 ratio. The stratified randomised block design will be applied, with stratified factors are surgical centre and the diameter of the main pancreatic duct measured by preoperative CT scan (preMPD). The primary outcome is the incidence of the clinically relevant pancreatic fistula.
ETHICS AND DISSEMINATION: Ethics Committee on Biomedical Research of West China Hospital of Sichuan University has approved this trial in March 2023 (approval no. 2023-167). Results of this trial will be published in peer-reviewed journals and conference proceedings.
TRIAL REGISTRATION NUMBER: NCT05808894.
<P>PROBLEM TO BE SOLVED: To overcome prior art defects and other defects by providing a new radiolabeling strategy for targeting the tissue for imaging.  <P>SOLUTION: A radiolabeled tissue-specific ligand, a method for preparing this radiolabeled ligand, a method of using this radiolabeled ligand for imaging tissue-specific diseases, and a composition for imaging tissue-specific diseases are provided. This imaging composition typically comprises ethylenedicysteine and a radionuclide label which is conjugated to the ethylenedicysteine on one or both acid arms and is chelated with a tissue-specific ligand. This ethylenedicysteine forms an N<SB>2</SB>S<SB>2</SB>chelate having the radionuclide label. Naturally, this chelate compound contains an ionic bond between the radionuclide and the chelate compound.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The present invention is a divisional application of the invention patent application No. 201510162612.5. The invention discloses soybean endophyte and application thereof, belonging to the technical field of microorganisms. A soybean endophyte is soybean seed endophyte, which is Bacillus cereus EnB-sy3(Bacillus cereus) and belongs to the genus Bacillus with the preservation number of CGMCC No. 10687. The soybean endophyte can obviously prolong the average life of caenorhabditis elegans, improve the heat resistance of the caenorhabditis elegans, can be planted in the body of the caenorhabditis elegans, and has wide prospect of being developed into health-care food or medicine.
Based on the in vitro activity against SARS-CoV-2 and preliminary clinical data, hydroxychloroquine is currently used in the management of COVID-19 patients. In the meantime, the efficacy as well as the dosage of hydroxychloroquine is highly debated. Because of the severity of COVID-19 and the pharmacokinetics of hydroxychloroquine in systemic lupus erythematosus patients, a loading dose was rapidly included in the new hospital regimens to optimize drug distribution in tissues and more precisely in the lungs. Due to the lack of information on the plasma/blood concentrations required to induce a virological/clinical effect, plasma/blood concentration is monitored in many European countries for patients whether or not they are included in clinical research protocols. This problem of relationship between efficacy and exposure is important in the critically ill patient because both the bioavailability and the variability of the pharmacokinetic parameters are potentially responsible for variations in concentrations.

This study is a prospective, observational, open, multisite, pharmacokinetics study of hydroxychloroquine in critically ill patients. There is no supplemental intervention or additional samples compared to the standard care of these patients in our teaching hospital. The total duration of the study is that of the duration of hospitalization in intensive care. The duration of the pharmacokinetic study is 9 days, starting on D1 of the treatment with hydroxychloroquine, and ending with the last recommended residual plasma control. The total duration of treatment with hydroxychloroquine is 10 days, as recommended by the High Council of Public Health in its opinion of March 23, 2020.
PURPOSE:To provide the subject new antibiotic 106-B exhibiting an antibacterial effect on Gram-positive and Gram-negative bacteria. CONSTITUTION:An antibiotic 106-B represented by the formula. The compound of the formula is obtained by culturing an antibiotic 106-B-producing bacterium (Streptomyces K106 strain. Stipulation No. is expected to given before long) belonging to Streptomyces and separating and collecting the antibiotic 106-B from the cultured material. The compound of the formula is used as the active component of an antibacterial agent.
There is substantial interest in preventing cardiovascular (CV) and renal disease progression in the Type 2 diabetic. Activation of the renin angiotensin aldosterone axis (RAS) and the mineralocorticoid receptor (MR) results in pro-inflammatory effects. Further the phenomenon of aldosterone escape provides a rationale for MR antagonism in addition to an ACEI/ARB agent. Agents that target the renin-angiotensin aldosterone system (RAAS) cascade have shown benefit in Type 2 Diabetics although combined RAS blockade such as using ACEI+ARB or ACEI/ARB+Renin inhibition have met with failure primarily owing to adverse effects such as hypotension and renal failure/hyperkalemia requiring dialysis. It has been speculated that dual RAS blockade or use of ACEI/ARB in conjunction with MRA may potentially be beneficial if one controls hyperkalemia and/or avoid excess hypotension. As a foundation for this current proposal, the investigators have demonstrated an important role for RAAS and MR antagonism in reducing atherosclerosis and inflammation in experimental animal models and limited studies in humans. The investigators are currently testing the efficacy of Spironolactone in reducing atherosclerosis on top of ACEI/ARB in high-risk patients with type 2 diabetes (T2DM) with concomitant CKD as part of a Randomized Double-blind controlled clinical trial. Given the fact that as much as 20-40% of a diabetic patient population with CKD may have problems of hyperkalemia on spironolactone, particularly those already on angiotensin converting enzyme inhibitor (ACEI)/ARB therapy, that would preclude their participation in this trial, the investigators would like to propose an open label supplemental arm to where patients who are ineligible for participation owing to baseline hyperkalemia or hyperkalemia on the dose escalation phase will be eligible to participate in the PRIMARY-Add on trial. The addition of Patiromer will enable introduction of MRA therapy at therapeutic doses and avoidance of hyperkalemia. The investigators thus propose a prospective open label trial with blinded assessment of end-points (PROBE) study which test the relative safety and efficacy of Patiromer on top of Spironolactone in T2DM on LV mass regression and occurrence of hypokalemia (Co-Primary End-points) as well as its effect on 24-hour ambulatory blood pressure (ABP) at 6 weeks, central aortic blood pressure at 6 weeks, atherosclerosis progression at 12 months and measures of monocyte inflammatory potential. If successful, the studies outlined in this proposal will extend the utility of Patiromer in high-risk diabetics at risk for future CV events and provide new information.
Chronic pain affects approximately 20% of both adults and children in the US and is a source of substantial disability and health care costs. Chronic pain can be challenging to diagnose due to the presence of poorly understood symptoms. When diagnosed, current pharmacologic treatments for pain are remarkably ineffective, while effective non-pharmacologic treatments remain under-utilized. These shortcomings in the diagnosis and treatment of pain arise from tremendous gaps in our knowledge about the basic central nervous system systems that process nociceptive information and instantiate an experience of pain. These gaps are further amplified in the case of pediatric chronic pain due to a lack of basic/translational research. The team of basic scientists and clinician scientists is uniquely positioned to perform human pediatric studies integrating functional neuroimaging with quantitative sensory testing and psychological assessments to delineate brain systems engaged during chronic pain. The study will examine four distinct chronic pain syndromes: migraine, complex regional pain syndrome, functional abdominal pain, and musculoskeletal pain. The study seeks to 1) Identify shared and distinct brain systems engaged by different forms of pediatric chronic pain, 2) Determine if predictors of recovery differ across different chronic pain conditions, 3) Delineate brain systems associated with the spread of pain. To accomplish these aims, the study will recruit 400 patients with chronic pain and 100 healthy participants (age range 10-17). The study will follow all participants longitudinally for 1 year after initiation of treatment to assess the degree of recovery and spread of pain. This basic science investigation will provide a critical foundation of basic knowledge for future clinical trials of diagnostic markers for different forms of chronic pain and for the development of new treatments for chronic pain.
The invention provides an active substance for the lung cancer and particularly belongs to the technical field of medicine. The active substance is medicine resistance and is obvious in synergism. The active ingredients of medicine include picropodophyllotoxin and erlotinib, wherein the weight part ratio of the picropodophyllotoxin and the erlotinib is 1:36-1:1.0. It is known through a cell level and nude mouse transplantation tumor experiment that when the picropodophyllotoxin and the erlotinib are combined for use, the growth of medicine resistance cells and medicine resistance nude mouse transplantation tumors can be effectively inhibited, an IGFIR signal path can be inhibited, and therefore the medicine resistance of the erlotinib is prevented or delayed. The invention further provides application of the combined use of the picropodophyllotoxin and the erlotinib in the lung cancer disease of people. After the picropodophyllotoxin and the erlotinib are combined for use, medicine resistance is low, no physiological toxicity exists, and therefore obvious economic value and social benefits are achieved.